UK Renal Registry

ILD119

People at highest risk from Covid-19 are eligible for fast access to Covid treatments if they test positive for the virus. The highest risk group includes people on kidney replacement therapy (KRT) (this includes those with kidney transplants and people on dialysis) and people with CKD stage 4 and 5. However, the evidence from clinical trials as to whether these drugs work well in this target population is limited due to small numbers. This study will use OpenSAFELY-UK Renal Registry (UKRR) linked data to further investigate the uptake, benefits and risks of COVID-19 antiviral treatment in this high-risk group. The analysis will be restricted to covid-infected patients both receiving KRT and with stages 4/5 CKD. We anticipate this will be at least 40000 patients, if not more. We will follow-up patients using the latest available data in OpenSAFELY. Results will be shared with NHSE as per standard policy for this service evaluation of antiviral roll-out, benefits and risks in people with advanced CKD and on RRT.